Myriad Genetics (MYGN) Misses Q1 EPS by 2c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $3.22 +1.90%
Financial Fact:
Molecular diagnostic testing: 165.1M
Today's EPS Names:
RIBT, INLB, FTXP, More
Financial Fact:
Molecular diagnostic testing: 165.1M
Today's EPS Names:
RIBT, INLB, FTXP, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q1 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $200.4 million versus the consensus estimate of $202.39 million.
GUIDANCE:
Myriad Genetics sees FY2026 revenue of $80.6-0.88 billion, versus the consensus of $1.53 billion.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic Signs $35b Cloud Deal With Lambda In Texas: WSJ
- Jefferies Upgrades TC Energy (TRP:CN) (TRP) to Buy
- Veritas Capital To Buy Bodycote For 940 Pence Per Share Value
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
